Milestone Pharmaceuticals Inc

NASDAQ MIST

Download Data

Milestone Pharmaceuticals Inc Accounts Payable Turnover Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Milestone Pharmaceuticals Inc Accounts Payable Turnover Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Milestone Pharmaceuticals Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.55, a -79.67% change year over year.
  • Milestone Pharmaceuticals Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 2.71, a 0.00% change year over year.
  • Milestone Pharmaceuticals Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.00, a 0.00% change year over year.
  • Milestone Pharmaceuticals Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.00, a 0.00% change year over year.
NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO Mr. Joseph G. Oliveto M.B.A.
IPO Date May 9, 2019
Location Canada
Headquarters 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees 47
Sector Healthcare
Industry Biotechnology
Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Similar companies

DMAC

DiaMedica Therapeutics Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

CMPX

Compass Therapeutics Inc.

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email